Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Back

Showing results (91-100 of 147) with videos related to

Pageof 15
Sort By:
HIV Clinical Trials|August 2, 2012
Alterations in cerebrospinal fluid chemokines are associated with maraviroc exposure and in vivo metabolites measurable by magnetic resonance spectroscopyJaime H Vera, Lucy J Garvey, Joanna M Allsop, et al.
British Journal of Clinical Pharmacology|December 21, 2004
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjectsMarta Boffito, David Back, Meredith Stainsby-Tron, et al.
The Journal of Antimicrobial Chemotherapy|March 11, 2014
Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteersAkil Jackson, Antonio D'Avolio, Graeme Moyle, et al.
Antiviral Therapy|July 21, 2004
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimenMarta Boffito, Laura Dickinson, Andrew Hill, et al.
The Journal of Antimicrobial Chemotherapy|June 18, 2011
Ageing with HIV: medication use and risk for potential drug-drug interactionsCatia Marzolini, David Back, Rainer Weber, et al.
The Journal of Antimicrobial Chemotherapy|December 16, 2011
Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studiesStephen Taylor, Ashini Jayasuriya, Martin Fisher, et al.
Antimicrobial Agents and Chemotherapy|May 22, 2013
Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokineticsGraeme Moyle, Laura Else, Akil Jackson, et al.
The Journal of Antimicrobial Chemotherapy|June 26, 2015
Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spotsAdeniyi Olagunju, Alieu Amara, Catriona Waitt, et al.
Genomics|April 1, 2010
Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarraysSaliha Yilmaz, Marta Boffito, Sophie Collot-Teixeira, et al.
Antiviral Therapy|August 24, 2007
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patientsLauro J Waters, Graeme Moyle, Stefano Bonora, et al.
Pageof 15

Showing results (91-100 of 147) with videos related to

Sort By:
Pageof 15
HIV Clinical Trials|August 2, 2012
Alterations in cerebrospinal fluid chemokines are associated with maraviroc exposure and in vivo metabolites measurable by magnetic resonance spectroscopyJaime H Vera, Lucy J Garvey, Joanna M Allsop, et al.
British Journal of Clinical Pharmacology|December 21, 2004
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjectsMarta Boffito, David Back, Meredith Stainsby-Tron, et al.
The Journal of Antimicrobial Chemotherapy|March 11, 2014
Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteersAkil Jackson, Antonio D'Avolio, Graeme Moyle, et al.
Antiviral Therapy|July 21, 2004
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimenMarta Boffito, Laura Dickinson, Andrew Hill, et al.
The Journal of Antimicrobial Chemotherapy|June 18, 2011
Ageing with HIV: medication use and risk for potential drug-drug interactionsCatia Marzolini, David Back, Rainer Weber, et al.
The Journal of Antimicrobial Chemotherapy|December 16, 2011
Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studiesStephen Taylor, Ashini Jayasuriya, Martin Fisher, et al.
Antimicrobial Agents and Chemotherapy|May 22, 2013
Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokineticsGraeme Moyle, Laura Else, Akil Jackson, et al.
The Journal of Antimicrobial Chemotherapy|June 26, 2015
Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spotsAdeniyi Olagunju, Alieu Amara, Catriona Waitt, et al.
Genomics|April 1, 2010
Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarraysSaliha Yilmaz, Marta Boffito, Sophie Collot-Teixeira, et al.
Antiviral Therapy|August 24, 2007
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patientsLauro J Waters, Graeme Moyle, Stefano Bonora, et al.
Pageof 15